Terms: = Head and neck cancer AND NFE2L2, ENSG00000116044, 4780, Q16236, NRF2
284 results:
1. cancer-associated fibroblasts secrete FGF5 to inhibit ferroptosis to decrease cisplatin sensitivity in nasopharyngeal carcinoma through binding to FGFR2.
Liu F; Tang L; Liu H; Chen Y; Xiao T; Gu W; Yang H; Wang H; Chen P
Cell Death Dis; 2024 Apr; 15(4):279. PubMed ID: 38637504
[TBL] [Abstract] [Full Text] [Related]
2. Therapeutic targeting of thioredoxin reductase 1 causes ferroptosis while potentiating anti-PD-1 efficacy in head and neck cancer.
Hsieh MS; Ling HH; Setiawan SA; Hardianti MS; Fong IH; Yeh CT; Chen JH
Chem Biol Interact; 2024 May; 395():111004. PubMed ID: 38636790
[TBL] [Abstract] [Full Text] [Related]
3. Differential squamous cell fates elicited by nrf2 gain of function versus KEAP1 loss of function.
Takahashi J; Suzuki T; Sato M; Nitta S; Yaguchi N; Muta T; Tsuchida K; Suda H; Morita M; Hamada S; Masamune A; Takahashi S; Kamei T; Yamamoto M
Cell Rep; 2024 Apr; 43(4):114104. PubMed ID: 38602872
[TBL] [Abstract] [Full Text] [Related]
4. Nobiletin alleviates cisplatin-induced ototoxicity via activating autophagy and inhibiting nrf2/GPX4-mediated ferroptosis.
Song W; Zhang L; Cui X; Wang R; Ma J; Xu Y; Jin Y; Wang D; Lu Z
Sci Rep; 2024 Apr; 14(1):7889. PubMed ID: 38570541
[TBL] [Abstract] [Full Text] [Related]
5. IL-1α facilitates GSH synthesis to counteract oxidative stress in oral squamous cell carcinoma under glucose-deprivation.
Ji Y; Zhang Z; Zhao X; Li Z; Hu X; Zhang M; Pan X; Wang X; Chen W
Cancer Lett; 2024 May; 589():216833. PubMed ID: 38548217
[TBL] [Abstract] [Full Text] [Related]
6. Combined genetic polymorphisms of the GSTT1 and nrf2 genes increase susceptibility to cisplatin-induced ototoxicity: A preliminary study.
Fujikawa T; Ito T; Okada R; Sawada M; Mohri K; Tateishi Y; Takahashi R; Asakage T; Tsutsumi T
Hear Res; 2024 Apr; 445():108995. PubMed ID: 38518393
[TBL] [Abstract] [Full Text] [Related]
7. [Clinicopathological and molecular characteristics of esophageal carcinoma with ductal differentiation: analysis of 17 cases].
Jiang WJ; Ao S; Cui YY; Lu L; Wang CN
Zhonghua Bing Li Xue Za Zhi; 2024 Mar; 53(3):276-281. PubMed ID: 38433056
[No Abstract] [Full Text] [Related]
8. Targeting nrf2 to treat thyroid cancer.
Gong Z; Xue L; Li H; Fan S; van Hasselt CA; Li D; Zeng X; Tong MCF; Chen GG
Biomed Pharmacother; 2024 Apr; 173():116324. PubMed ID: 38422655
[TBL] [Abstract] [Full Text] [Related]
9. Quantitative US Delta Radiomics to Predict Radiation Response in Individuals with head and neck Squamous Cell Carcinoma.
Osapoetra LO; Dasgupta A; DiCenzo D; Fatima K; Quiaoit K; Saifuddin M; Karam I; Poon I; Husain Z; Tran WT; Sannachi L; Czarnota GJ
Radiol Imaging Cancer; 2024 Mar; 6(2):e230029. PubMed ID: 38391311
[TBL] [Abstract] [Full Text] [Related]
10. m6A/HOXA10-AS/ITGA6 axis aggravates oxidative resistance and malignant progression of laryngeal squamous cell carcinoma through regulating Notch and Keap1/nrf2 pathways.
Zhao K; Chen L; Xie Y; Ren N; Li J; Zhai X; Zheng S; Liu K; Wang C; Qiu Q; Peng X; Wang W; Liu J; Che Q; Fan J; Hu H; Liu M
Cancer Lett; 2024 Apr; 587():216735. PubMed ID: 38369001
[TBL] [Abstract] [Full Text] [Related]
11. ARID1A loss is associated with increased nrf2 signaling in human head and neck squamous cell carcinomas.
Nguyen V; Schrank TP; Major MB; Weissman BE
PLoS One; 2024; 19(2):e0297741. PubMed ID: 38358974
[TBL] [Abstract] [Full Text] [Related]
12. Nuclear factor erythroid 2-related factor 2 promotes radioresistance by regulating glutamate-cysteine ligase modifier subunit and its unique immunoinvasive pattern.
Xue Z; Nuerrula Y; Sitiwaerdi Y; Eli M
Biomol Biomed; 2024 May; 24(3):545-559. PubMed ID: 38340316
[TBL] [Abstract] [Full Text] [Related]
13. CTC together with Shh and nrf2 are prospective diagnostic markers for HNSCC.
Rahman MM; Hossain MM; Islam S; Ahmed R; Majumder M; Dey S; Kawser M; Sarkar B; Himu MER; Chowdhury AA; Ahmed S; Biswas S; Anwar MM; Hussain MJ; Kumar Shil R; Baidya S; Parial R; Islam MM; Bharde A; Jayant S; Aland G; Khandare J; Uddin SB; Noman ASM
BMC Mol Cell Biol; 2024 Feb; 25(1):4. PubMed ID: 38336617
[TBL] [Abstract] [Full Text] [Related]
14. nrf2 Activation in Trp53;p16-deficient Mice Drives Oral Squamous Cell Carcinoma.
Hamad SH; Sellers RS; Wamsley N; Zolkind P; Schrank TP; Major MB; Weissman BE
Cancer Res Commun; 2024 Feb; 4(2):487-495. PubMed ID: 38335300
[TBL] [Abstract] [Full Text] [Related]
15. CYLD induces high oxidative stress and DNA damage through class I HDACs to promote radiosensitivity in nasopharyngeal carcinoma.
Li Y; Yang C; Xie L; Shi F; Tang M; Luo X; Liu N; Hu X; Zhu Y; Bode AM; Gao Q; Zhou J; Fan J; Li X; Cao Y
Cell Death Dis; 2024 Jan; 15(1):95. PubMed ID: 38287022
[TBL] [Abstract] [Full Text] [Related]
16. Piperlongumine inhibits esophageal squamous cell carcinoma in vitro and in vivo by triggering nrf2/ROS/TXNIP/NLRP3-dependent pyroptosis.
Cui Y; Chen XB; Liu Y; Wang Q; Tang J; Chen MJ
Chem Biol Interact; 2024 Feb; 390():110875. PubMed ID: 38242274
[TBL] [Abstract] [Full Text] [Related]
17. Uncovering immune checkpoint heterogeneity in oral squamous cell carcinoma using single cell RNA-sequencing data highlights three subgroups of patients with distinct immune phenotypes.
Le Meitour Y; Foy JP; Guinand M; Michon L; Karabajakian A; Fayette J; Saintigny P; Mahtouk K
Oral Oncol; 2024 Feb; 149():106680. PubMed ID: 38218022
[TBL] [Abstract] [Full Text] [Related]
18. MiR-630 Promotes Radioresistance by Induction of Anti-Apoptotic Effect via nrf2-GPX2 Molecular Axis in head-neck cancer.
You GR; Cheng AJ; Shen EY; Fan KH; Huang YF; Huang YC; Chang KP; Chang JT
Cells; 2023 Dec; 12(24):. PubMed ID: 38132173
[TBL] [Abstract] [Full Text] [Related]
19. Identification of prognostic value of anoikis-related gene score model combined with tumor microenvironment score models in esophageal squamous cell carcinoma.
Zhang M; Liang Y; Song P
J Gene Med; 2024 Jan; 26(1):e3624. PubMed ID: 38087999
[TBL] [Abstract] [Full Text] [Related]
20. Brusatol attenuated proliferation and invasion induced by KRAS in differentiated thyroid cancer through inhibiting nrf2.
Gong Z; Xue L; Vlantis AC; van Hasselt CA; Chan JYK; Fang J; Wang R; Yang Y; Li D; Zeng X; Tong MCF; Chen GG
J Endocrinol Invest; 2024 May; 47(5):1271-1280. PubMed ID: 38062319
[TBL] [Abstract] [Full Text] [Related]
[Next]
